Compare Roundhill Innov-100 0DTE Covered Call Strat ETF (QDTE) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Roundhill Innov-100 0DTE Covered Call Strat ETF vs BIO-TECHNE Corp — how do they compare? Roundhill Innov-100 0DTE Covered Call Strat ETF trades at $29.57, while BIO-TECHNE Corp trades at $71.73 (market cap $11.16B). The key difference: BIO-TECHNE Corp pays a 0.45% dividend while Roundhill Innov-100 0DTE Covered Call Strat ETF pays none, and BIO-TECHNE Corp is trading nearer its 52-week high, Roundhill Innov-100 0DTE Covered Call Strat ETF nearer its low. Which is the better fit depends on your goals.
| QDTE | TECH | |
|---|---|---|
Sector | Income / Options Overlay | Health |
52-Week High | $36.60 | $72.12 |
52-Week Low | $26.85 | $43.31 |
Market Cap | — | $11.16B |
Enterprise Value | — | $11.24B |
Dividend Yield | — | 0.45% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
QDTE trades at $29.22, up 0.31% on the day, with technical indicators signaling a bearish trend. The ETF employs a weekly covered call strategy on the Innovation-100 index, generating high distribution yields. Recent news highlights scrutiny over its fee structure and yield sustainability amid declining volatility. Key financial ratios are unavailable in the provided data, limiting fundamental assessment.
The outlook is cautious due to bearish technicals and yield compression risks. Opportunities exist for income-focused investors seeking weekly distributions, but risks include fee drag and volatility dependence. Investor sentiment is mixed, with media questioning yield math while acknowledging competitive returns in certain periods.
Bio-Techne (TECH) trades at $71.63, down 0.68% on the day, near its all-time high following a $73 per share acquisition offer from Merck KGaA. The stock shows bullish technical signals with strong moving averages and ADX trends. Fundamentally, the company reported mixed quarterly earnings but maintains solid gross margins of 64.96%. Recent news is dominated by the proposed $11.3 billion buyout, driving significant investor interest and legal scrutiny over the transaction's fairness.
The outlook is heavily influenced by the pending acquisition, with upside capped near the $73 offer price. Risks include shareholder litigation and regulatory approval delays. Analyst consensus is split evenly between Buy and Hold, reflecting uncertainty around deal completion. The stock presents a potential arbitrage opportunity if the acquisition proceeds, but carries event risk if the transaction fails.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Roundhill Innov-100 0DTE Covered Call Strat ETF
QDTE is an actively managed ETF that seeks to generate income through a covered call strategy on the NASDAQ 100. It primarily holds a portfolio of U.S. government securities and sells 0-DTE (zero days to expiration) index call options on the NASDAQ 100. This highly tactical strategy aims to maximize option premium capture by exploiting the rapid time decay of options expiring on the same day, which provides enhanced income but also exposes the fund to significant volatility and risks associated with daily options settlement.
Read more on QDTE →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
